Title Director, Melanoma and Skin Cancer Program - Director, Center for Immuno-Oncology Research
Department Hematology and Medical Oncology
Primary Location Cleveland Clinic Main Campus
Type of Doctor Adults Only
Languages English
Surgeon No
Locations Specialties & Treatments

Treatment & Services

  • Cancer Center
  • Chemotherapy
  • Clinical Drug Trials
  • Immunotherapy
  • Targeted Treatment
View all 5 Treatment & Services +

Specialty in Diseases & Conditions

  • Cancer
  • Melanoma
  • Skin Cancer
View all 3 Specialties +


Is Cleveland Clinic Part of Your Insurance?

Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.

View All Plans

About Ahmad Tarhini, MD, PhD

Dr Tarhini is Professor of Medicine at Cleveland Clinic Lerner School of Medicine of Case Western Reserve University. He serves as Director of Melanoma and Skin Cancer Program and Director of the Center for Clinical and Translational Immuno-Oncology Research at the Cleveland Clinic Taussig Cancer Institute.  Before joining CCF, he had been a Tenured Associate Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh and Director of Clinical Sciences of the Pennsylvania Cancer Consortium. Dr Tarhini has a Master of Science and a PhD in Clinical and Translational Science from the University of Pittsburgh School of Medicine (UPSOM).

Dr Tarhini has lead multiple clinical trials and biomarker studies in the field of Immuno-Oncology and has investigated the role of promising biomarkers in relation to disease risk and clinical benefits of immunotherapy in the melanoma adjuvant, neoadjuvant, and advanced disease settings. His original work on immunotherapy of melanoma and biomarkers of disease prognosis and therapeutic benefit has been published in high-impact, peer-reviewed journals and presented at leading national/international meetings. He serves as a chair/co-chair on several cooperative group trials, including U.S. Intergroup clinical trials E1609, S1404, EA6141, E3612, E3611, NCI8628 and NCI10061. He is the Principal Investigator for the NCI ExperimentalTherapeutics Clinical Trials Network (ETCTN) grant for Case Comprehensive Cancer Center.

Education & Professional Highlights

Education & Professional Highlights


Education & Fellowships

Graduate - University of Pittsburgh School of Medicine
Pittsburgh, PA USA

Graduate - University of Pittsburgh School of Medicine
Pittsburgh, PA USA

Fellowship - University of Pittsburgh Cancer Institute
Hematology/ Medical Oncology
Pittsburgh, PA USA

Residency - University of Pittsburgh Medical Center
Internal Medicine
Pittsburgh, PA USA

Medical School - Kaunas University of Medicine
Kaunas, Lithuania

Undergraduate - American University of Beirut
Beirut, Lebanon

Professional Highlights

  • Dr Tarhini has been closely involved in the education, mentoring and advancing the careers of PhD students, post-doctoral students, medical students, internal medicine residents and hematology-oncology fellows. The outcomes of these mentoring activities can be measured in the form of peer reviewed publications, proceedings of national meetings and funded grants. He served as the course director for MED 5831 Medical Oncology Research (2010 – 2017) and MED 5715 Neoplasia and Neoplastic Disease (2011 – 2017) at UPSOM. He served as the founder and course co-Director of the Nazarbayev University Oncology Course (UPSOM - Nazarbayev Univ. collaboration).


  • Internal Medicine - Medical Oncology

Specialty Interests

Director, Melanoma and Skin Cancer Program Director, Center for Immuno-Oncology Research

Awards & Honors

  • Dr Tarhini completed his residency training in Internal Medicine at the University of Pittsburgh Medical Center (UPMC). Upon graduation, he was awarded the Resident of the Year award. During his Hematology and Oncology fellowship training at UPMC, he was awarded a fellowship by the NIH-funded University of Pittsburgh’s Clinical and Translational Science Institute (CTSI), achieving a Master of Science in clinical research. He was also awarded a competitive grant towards the ASCO/AACR Workshop — Methods in Clinical Research in Vail, Colorado. In 2006, he was awarded the American Society of Clinical Oncology (ASCO) Foundation Merit Award.

    Dr Tarhini’s efforts were also awarded by being presented the 2009 University of Pittsburgh Cancer Institute Junior Scholar Award in Clinical Research and the 2010 Eastern Cooperative Oncology Group (ECOG) Research and Education Foundation Young Investigator Award.

    He was elected to serve as Track Leader of the American Society of Clinical Oncology (ASCO)’s Cancer Education Committee Melanoma/Skin Cancers Track and he is a member of the Scientific Committee.


  • American Society of Clinical Oncology (ASCO)
  • American Association of Cancer Research (AACR)
  • Cytokine Working Group (CWG)
  • Eastern Cooperative Oncology Group - American College of Radiology Imaging Network (ECOG -ACRIN)
  • Society for Immunotherapy of Cancer (SITC)
Research & Publications

Research & Publications

See publications for Ahmad Tarhini, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 1/17/2018, Dr. Tarhini has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Patient Satisfaction Reviews

56 Patient Satisfaction Reviews

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.

Overall Star Ratings
4.8 out of 5
Explains 4.8
Listens 4.9
Courtesy, Respect & Concern 4.9
Knows Medical History 4.8
Time Spent with Patient 4.9
Patient Rating of Doctor 4.9

1 Patient Comment

Reviewed on Jun 20, 2018

I feel very lucky to have Doctor Tarhini help me - he is an amazing specialist , with a wealth of knowledge in melanoma treatment. I feel I have the very best care. the location of your Cancer Center is hard to get to from major roadways.

Related Videos Featuring Ahmad Tarhini, MD, PhD

Related Videos Featuring Ahmad Tarhini, MD, PhD

Back to Top